Anuh Pharma Limited has made a regulatory disclosure to BSE Limited and National Stock Exchange of India Limited pursuant to Regulation 30 of SEBI LODR Regulations, 2015.
The Board of Directors of the company held a meeting on Tuesday, 13th October, 2026, which commenced at 03:30 p.m. and concluded at 04:35 p.m.
During this meeting, the board approved two key items:
1. Investment in manufacturing assets for expansion of the company's production capacity
2. Proposal to avail a loan of up to ₹75 crores (Rupees Seventy Five Crores) specifically for the purchase of manufacturing assets to expand production capacity
The loan approval is subject to finalization of terms and conditions and receipt of applicable approvals where required.
The company has stated that requisite details and annexures, to the extent applicable under SEBI LODR Regulations, 2015, shall be disclosed based on the actual details of the transaction.
This disclosure has been digitally signed by Manan Jayesh Vadhan, Company Secretary & Compliance Officer of Anuh Pharma Limited, on October 13, 2026, at 18:26:39 IST, and is being uploaded on the company's website at www.anuhpharma.com.